

Reig Jofre increases its capital amounting to euros 24 million to finance its expansion plan

- The capital increase that was carried out by private placement procedure among qualified investors from Spain and the rest of Europe, has given entrance into Reig Jofre's shareholder base to the Family Office Onchena and to the Swiss investment fund Quaero Capital, among others
- Following the capital increase, Reig Jofre Investments, the majority shareholder, diluted its stake up to 62.7% and the free float increased up to 21.3% compared to 15.7% prior to the transaction

Barcelona (Spain), June 17, 2019. Reig Jofre, pharmaceutical company listed on the Spanish stock exchange market, announced a capital increase for an amount of 24 million euros. The increase has been aimed at qualified investors from Spain and the rest of Europe, interested in taking a significant stake and accompanying the growth and expansion project of Reig Jofre.

key investors

The capital increase allowed the entry into the shareholding, among others, to family offices such as **Onchena**, whose long-term investment philosophy seeks to accompany solid business projects in specific sectors; as well as to institutional investors such as the Swiss investment fund **Quaero Capital SA** specialized in European small and medium capitalization companies. The rest of the investors that signed up for the increase have been mainly relevant fund managers in the Spanish market. 23% of the capital increase has been subscribed by international investors, and the remaining 77% by national investors.

After the increase, the shareholding of the majority shareholder, Reig Jofre Investments, the investment vehicle of the Reig Jofre family, was diluted up to 62.7% of the capital compared to the previous 72.2%, Natra to 10.1%, and the free float rose from 15.7% prior to the increase to 21.3%, fulfilling so the will expressed frequently to the market, to increase the liquidity of the value and allow the entry of new partners interested in the project.



Purpose of the fund raising

The funds obtained will be used to finance future growth opportunities, both organic and inorganic, that will allow to continue expanding the Company's business areas with corporate actions that have a strategic fit and add value (i) expansion plans in the areas of specialty products (Skin, Hair and Nails Health and Women's Health) and Consumer Healthcare, which will strengthen the company's current presence in the markets of France, Spain, United Kingdom, Belgium, Nordic countries, Portugal and Southeast Asia; and (ii) to the ambitious investment plan of more than 60 million euros started in 2017 in the area of pharmaceutical technologies (specialized in sterile antibiotics and injectable products), which will conclude in 2020.

Reig Jofre closed 2018 with a turnover of 181 million euros, of which Spain accounted 41%, rest of Europe 48% and rest of the world 11%. To market its developments, Reig Jofre has its own sales network in 7 countries of Europe and Southeast Asia, and commercial relations with more than 130 partners (distributors and licensees) in near 70 countries on the five continents.

Receive Reig Jofre's news by registering in the company's **subscription center** of the new corporate website: **www.reigjofre.com**

About Reig Jofre

Founded in 1929 in Barcelona, Reig Jofre is a pharmaceutical company publicly listed on the Spanish stock exchange, devoted to the research, development, manufacture and marketing of pharmaceutical products and nutritional supplements. Reig Jofre structures its product development activity in three business areas: pharmaceutical technologies specialized in the development and manufacture of sterile and lyophilized injectable pharmaceutical products, as well as antibiotics derived from penicillin. Specialty products focused on the research, development, manufacture and commercialization of specialties in dermatology (skin, hair and nails) and gynecology (women's health), mainly. And, Consumer Healthcare in which highlights the line of nutritional supplements marketed under the brand Forté Pharma mostly in France, Belgium, Spain and Portugal, as well as other OTC products. Reig Jofre has more than 1,000 employees, 4 development and manufacturing centers in Europe (2 in Toledo, 1 in Barcelona and 1 in Sweden), direct sales in 7 countries and over 130 commercial partners in 70 countries worldwide. The company reached sales of €181 M in 2018. Reig Jofre trades on the Spanish stock exchange under the ticker RJF. Total outstanding shares: 76,062,457 shares

For further information

Inma Santa-Pau - Head of Communication and Investor Relations
Tel. (+34) 93 480 67 10 (ext. 1242) - inma.santapau@reigjofre.com